Amol Akhade/LinkedIn
Jul 5, 2025, 19:18
Amol Akhade: CRC Screening Face-Off: Stool vs Blood
Amol Akhade, Consultant Medical Oncologist Hemato Oncologist at Suyog Cancer Clinics, shared on X:
“CRC Screening Face-Off: Stool vs Blood
Not all non-invasive tests are created equal.
Let’s break it down:
CRC Sensitivity
- Cologuard Plus: 95%
- ColoSense: 94%
- Shield (blood): 80–83%
- FIT: 67–91%
Advanced Adenoma Detection (PREVENTION!)
- ColoSense: 46%
- Cologuard: 43%
- FIT: 20–30%
- Shield: 13–16%
High-Grade Dysplasia
- Cologuard: 74%
- FIT: 47%
- Shield: 23%
- ColoSense: Not Available
Specificity
- FIT: 95%
- Shield: 90%
- Cologuard: 91–94%
- ColoSense: 88%
Verdict:
Blood-based cfDNA is convenient but underperforms where it matters – early detection of pre-cancer.
Cologuard and ColoSense are clear leaders in prevention.
If we want to prevent, not just detect, CRC – stool-based testing still beats.”
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52
Jul 5, 2025, 18:38